Mihriban Karaayvaz

Title: Mihriban Karaayvaz: Innovator in Colorectal Cancer Research

Introduction

Mihriban Karaayvaz is a prominent inventor based in Stony Brook, NY (US). She has made significant contributions to the field of cancer research, particularly in identifying biomarkers for colorectal cancer. Her innovative work has the potential to improve treatment outcomes for patients diagnosed with this disease.

Latest Patents

Karaayvaz holds a patent titled "MicroRNA-129 as a biomarker for colorectal cancer." This patent describes methods for identifying subjects who would benefit from treatment with chemotherapeutic agents. The research highlights that miR-129 expression levels are reduced in colorectal cancer, leading to the development of therapeutic compositions and methods for altering the expression of a miR-129 effector. The patent also outlines methods for characterizing the stage of colorectal cancer based on miR-129 expression levels. Furthermore, it identifies miR-129 as a predictive biomarker for cancer diagnosis and treatment with directed therapeutic agents.

Career Highlights

Karaayvaz is affiliated with the State University of New York, where she continues her research and development in cancer therapeutics. Her work is crucial in advancing the understanding of colorectal cancer and improving treatment strategies.

Collaborations

Some of her notable coworkers include Jingfang Ju and Haiyan Zhai, who contribute to her research efforts in the field of cancer biomarkers.

Conclusion

Mihriban Karaayvaz is a key figure in colorectal cancer research, with her innovative patent on miR-129 offering new avenues for diagnosis and treatment. Her contributions are vital for the ongoing fight against cancer, and her work continues to inspire advancements in medical science.